TG Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 5 →InsidersNo open-market buys. 2 insiders sold $437,650, 0 of 2 sales on a 10b5-1 plan.→HoldersBlackRock 14.4%Vanguard Portfolio 5.2%State Street 5.1%→PeersClosest companies: KAPA, AVTX, RVMD→
From the filings
Figures
- Revenue
- $799.5Mlast 12 months
- Net income
- $441.5Mlast 12 months
- Operating cash flow
- −$14.0Mlast 12 months
- Cash and equivalents
- $482.6Mat the last balance sheet
- Total debt
- $745.4Mat the last balance sheet
- Shares outstanding
- 153.1M shareson issue